Ocuphire Pharma, Inc. Annual report pursuant to Section 13 and 15(d)

Company Description and Summary of Significant Accounting Policies, Warrant Liabilities and Premium Conversion Derivatives Measured at Fair Value (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2022
Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]
Reclassification of warrants from liability to equity	$ 61,793
Level 3 [Member] \| Warrant Liabilities [Member]
Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]
Balance as of beginning of period	27,964
Change in fair value of warrant liabilities	33,829
Reclassification of warrants from liability to equity	(61,793)
Balance as of end of period	0
Nonrecurring Basis [Member]
Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]
Financial instruments liabilities at fair value	$ 0	$ 0